NOTE: ALL STOCKS IN THIS WATCHLIST ARE EITHER TRENDING TOWARDS A BULLISH TECHNICAL CHART OR CURRENTLY IN ONE. ANY TECHNICAL ANALYSIS IS PROVIDED IN THE CHART. PLEASE DO YOUR OWN DUE DILIGENCE BEFORE CONSIDERING INVESTING IN THESE STOCKS. (The Shares Float is based on figures from FinViz.Com).
Stocks highlighted in this watchlist include $ITEK, $ATHX, $MTBX, $PSDV. I'm keeping $RGSE on the backburner looking for a potential reversal. Good Luck my friends.
So why has ITEK been so hot since mid-September? Simply, this September 12th NR. Inotek Pharmaceuticals Announces Merger Agreement with Rocket Pharmaceuticals to Advance Pipeline of First-in-Class Gene Therapies for Rare Diseases. The question really is, How valuable will the merged company be? Until we get that information, caution is recommended but there is lots of upside technically.
The Company announced that it has received the Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA, recently established under the 21st Century Cures Legislation. The RMAT designation may be obtained for eligible cell therapy and other regenerative medicine and advanced therapies when the FDA agrees that preliminary clinical evidence indicates that the therapy has demonstrated the potential to address unmet medical needs for a serious or life-threatening disease or condition. The designation enables sponsors to discuss with the FDA multidisciplinary strategic development plans, including expediting manufacturing development plans for commercialization to support priority review and accelerated approval.
In addition, Robert W. Mays, Ph.D., Vice President, Regenerative Medicine and Head of Neuroscience Programs is currently presenting at the annual Partnering Forum as part of the Cell & Gene Meeting on the Mesa being held from October 4-6 in La Jolla, California. Dr. Mays is providing a brief overview of the Company’s neuroscience programs, focusing on the Phase 3 clinical program for ischemic stroke, which previously received Special Protocol Assessment (SPA) and Fast Track designations from the U.S. Food and Drug Administration (FDA), and recently obtained a Final Scientific Advice positive opinion from the European Medicines Agency.
In case you don't know why the stock took off on Wednesday afternoon, here's the NR.
MTBC, a leading provider of mHealth and cloud-based clinical and practice management solutions, today announced the successful full launch of its next-generation, voice-enabled electronic health records (EHR) solution, talkEHR™. “We’re very pleased to have already signed new talkEHR clients representing 30 unique specialties, spanning across 42 states plus Guam and Puerto Rico. talkEHR is a phenomenal addition to our fully integrated, industry leading, cloud-based and mobile platform and we expect it to play an important role as we continue to expand our customer base.”
In addition, they also announced that one of the 10 largest insurance carriers in the United States has entered into a contract with MTBC to leverage MTBC’s EnrollmentPlus™ software-as-a-service (SaaS) solution.
Pro-Trader Daily has just published a post-earnings coverage on pSivida Corp. following the Company's announcement of its fourth quarter and fiscal year 2017 financial results on September 11, 2017. The developer of sustained release drug products and technologies exceeded revenue expectations.
For the fourth quarter ended June 30, 2017, pSivida's revenue totaled $701,000 compared to $304,000 for Q4 FY16. The Company's revenue beat analysts' estimates of $0.48 million.